Join Our ICO

We are Creating the future of healthcare innovation


Vivo Capital ICO




Best Time To Invest Now!



Our ICO Ratings

Vivo Capital ICO rating Vivo Capital score on Foundico.com Vivo Capital ICO rating Vivo Capital ICO rating Vivo Capital ICO rating Vivo Capital ICO rating Vivo Capital ICO Rating Vivo Capital ICO Rating Vivo Capital ICO Rating

About Vivo Capital

Founded in 1996, Vivo Capital is a healthcare investment firm focused on investing in and building high quality companies in the U.S. and China. With more than $1.7 billion under management, Vivo employs a unique multi-pronged strategy of identifying and working with companies with promising development stage and commercial stage therapeutic products in the U.S. and revenue stage companies in China. Vivo Capital has offices in Palo Alto, California, Shanghai, and Beijing, China.

At Vivo Capital, we leverage our internal expertise in evaluating data to generate outsized returns for company founders and employees as well as for our investors. Vivo invests primarily in later development stage pharmaceutical and medical device companies in the U.S. and in revenue stage healthcare companies in greater China. Vivo assists its portfolio companies in both countries in forging cross-border partnerships, enabling the companies to acquire new products and expand the market for their existing products. In addition to making investments in existing companies, Vivo also builds companies from scratch to pursue compelling opportunities together with experienced management teams. Finally, a portion of every Vivo fund is invested directly into public therapeutics companies. Despite its focus on companies with later-stage products, Vivo is willing to work with companies (and their founders) that may not have significant infrastructure. We invest in companies with promising products at all financing stages (Series A to public companies), and work closely with founders and management to complete the development and commercial launch of those products and achieve a successful exit.

Vivo Capital is solving global healthcare business cash flow problems

MANUFACTURERS who have healthcare products want to sell it for their cash-flow.

Problem

The MANUFACTURER aims to obtain the best possible price for their healthcare products or services and to receive payment for these as soon as possible. The problem to the seller is that they will not be able to continue operating their business without a better cash-flow.

Solution

Through our investment platform we will connect the manufacturer directly with individual investors who will finance for the healthcare company. The manufacturer will be able to get 80% of the face value of each product as soon as registered on our investment platform, thereby reducing the risk that they will not have the money to cover their operating expenses while they are waiting to get paid.

INVESTORS are seeking for higher rates of return on their investment.

Problem

Investors are currently not able to directly invest in healthcare financing without establishing an healthcare financing business. In the traditional healthcare financing model, the risk is that the investor does not have a direct relationship with the manufacturers. The investor solely trusts the information provided by the manufacturer. This exposes the investor to a considerable risk of the interest not being paid as agreed, or being disputed by manufacturers.

Solution

Through our investment platform, investors will be granted access to an investment product that is for the most part currently only available to the healthcatre companies. Each investor will be able to invest in a number of loan fragments from a large number of diverse businesses across various healthcare industry sectors. Our platform’s loan fragmentation algorithm will automatically match the investor’s risk and investment profile with a predicted return on investment.

BUYERS are facing big challenges for making their payment for healthcare products.

Problem

The buyer wants to obtain the lowest possible price for their healthcare products purchase and also delay the payment of manufacturers for the lack of cash-flow. The risk to the buyer is that they may not have sufficient cash available for payment on delivery or shortly thereafter.

Solution

Once the buyers has access to our platform, the manufacturer is in a position to get paid for their products, thereby optimising the buyer’s cash-flow position. Buyers will get loans from our investment platform with a low interest rate. Our platform’s loan fragmentation algorithm will automatically match the buyers loan profile with a predicted return on our investment.

Press & Media

Vivo Capital Tokens

We are Creating the future of healthcare innovation

Token Name

VivoCapital

Token Ticker

VCT

Contract Address :

0x177fbcf0f8ae1c7bcc042b5612ef80b3ff5b9583

Total Supply

88B VCT Tokens

Token Network

Ethereum (ERC-20)

Token Distribution

Tokens will be distribute instantly.

Token Price

1 ETH = 50,000 VCT + any bonuses

Bonus Lock-up

No bonus lock-ups below 100ETH

VCT Token
Distribution

  • 30% Marketing30
  • 40% Investment Fund40
  • 15% System Development15
  • 14% Services14
  • 1% Bounty1

VCT Initial Token Offering

Become an early adopter.

Take part in the ICO to get your early membership to the platform.

VCT Private Sale

Minimum Invest : 1 ETH

Maximum Invest : 2,000 ETH

Allocation : 24,000,000,000 VCT

VCT Pre-Sale

Minimum Invest : 0.1 ETH

Maximum Invest : 10,000 ETH

Allocation : 24,000,000,000 VCT

VCT Main Sale

Minimum Invest : 0.1 ETH

Maximum Invest : 20,000 ETH

Allocation : 52,000,000,000 VCT

VCT Token Sale Timeline & Bonus Structure

Stage 1 (Private Sale)

15/09/18

to

30/09/18

40% BONUS

Stage 2 (Pre-Sale)

01/10/18

to

15/10/18

20% BONUS

Stage 3 (Main Sale)

16/10/18

to

15/11/18

10% BONUS

Stage 4 (Main Sale)

16/11/18

untill

Hardcap

5% BONUS

Roadmap

Curious to Learn Even More?

Vivo Capital Team

The experts are creating the future of healthcare innovation.

Lawrence Wang

Managing Director

Michael Chang

Managing Director

Jack Bech Nielsen

Managing Director

Gaurav Aggarwal

Managing Director

Frank Kung

Managing Partner

Albert Cha

Managing Partner

Shan Fu

Managing Partner

Chen Yu

Managing Partner

Derek Yang

Finance Director

Peiyi Zhao

Head of Legal

Albert Chang

Managing Partner

Edgar G. Engleman

Managing Partner

Mahendra G. Shah

Managing Director

Hwachie Lee

Managing Director

Jo Shen

Venture Partner

Yuh-geng Tsay

Venture Partner

Tracy Wu

General Director

Joseph Siletto

Managing Director

Daisy Xu

General Director

Our Advisor, Analyst & Associates

Super experienced. Always one step ahead.

Nathan Dau

Associate

Eric Trac

Associate

Tiantian Zhu

Analyst

Ethan Zhao

Associate

Tierney Y. Li

Analyst

Andrew D. Goldberg

Principal

Vinayak Nikam

Associate

Adrianne Chang

Consultant

Dan Dan Dong

Principal

Qi Zhu

Principal

Nina Feng

Principal

Kevin Dai

Principal

David Liu

Principal

Daniel Qin

Associate

Lingfei Zhao

Analyst

Sue Shao

Associate

Yixuan Li

Analyst

Waika Cheng

Analyst

Xiaoyang Li

Analyst

Cyber Cao

Senior Associate

Aaron Royston

Senior Associate

Ronghuan Lin

Advisor

Bonus Timeline

15.09.2018

Private-sale
40% Bonus

Ends 30.09.2018

01.10.2018

Pre-sale
20% Bonus

Ends 15.10.2018

16.10.2018

Crowdsale
10% Bonus

Ends 15.11.2018

16.11.2018

Crowdsale
5% Bonus

untill Hardcap

10.06.2018

Crowdsale
0% Bonus

until ICO concludes

Our Partners

Bringing Vivo Capital to all Corners of the world.

Want to lear more? Join the conversation on Telegram

We are Creating the future of healthcare innovation.